However, other studies have shown that treatment with the PPARγ agonist rosiglitazone and troglitazone, or conversely with PPARγ antagonists GW9662 and T0070907, were both found to significantly inhibit the growth of a wide variety of cancer cell lines [10, 11]. The gene discussed is PPARG; the disease is cancer.